StockLens

Cipla Limited (CIPLA) share price and analysis

CIPLA last traded at ₹1,388.00 (-0.47%) on the NSE. Market cap ₹1,12,135 Cr (Large cap), Pharma & Healthcare sector.

Overall rating: 5.1/10 (Average)

Long-term view: Neutral (watchlist). A mixed picture. Wait for better value or a clearer trend. Trade bias (next few weeks): Long bias. Conditions favour buying dips over shorting.

Strengths of CIPLA

Weaknesses of CIPLA

Key numbers

NumberValueAssessmentNormal range
P/E (TTM)38.7In line with peers37.0–49.3 (sector median 41.1)
Forward P/E22.3Profits expected to growbelow today's P/E (38.7) and near 41
Price / book3.17Normal2–6
EPS (TTM)₹35.84Profitableabove ₹0
Return on equity8.3%Weak15%+ (below 10% is weak)
Debt / equity0.02Low debtbelow 1.0 (under 0.5 is great)
Net margin10.4%Healthy10%+ (below 5% is thin)
Operating margin13.0%Average20%+ strong, below 10% thin
Revenue growth-1.1%Shrinking10%+ a year (below 3% is weak)
Profit growth-35.0%Falling10%+ a year (falling is weak)
Dividend yield0.93%Small payout1.5%+ (none is fine for growth firms)
Current ratio3.59Comfortable1.5+ (below 1 is tight)
52W high₹1,539.7010% below · mid-rangeprice in the top 40% of its 52-week range
52W low₹1,165.70Price is 19% above it
50-DMA₹1,365.74Price 1.6% aboveprice above it = short-term uptrend
200-DMA₹1,363.98Price 1.8% aboveprice above it = long-term uptrend
1Y return-8.2%Lagged the Nifty 50Nifty 50 did −0.4%
Beta0.10Steadier than the market0.8–1.3 (1 = moves with market)
Promoter / insider31.1%Moderate stake50%+ shows owner commitment
Institutions45.0%Strong big-investor interest30%+ is strong
Analyst target₹1,507.318.6% upside · 36 analysts8%+ upside

Questions about CIPLA

What is the share price of Cipla Limited (CIPLA) today?

CIPLA last traded at ₹1,388.00 (-0.47% on the day) on the NSE. Its 52-week range is ₹1,165.70 to ₹1,539.70. Prices are delayed and come from Yahoo Finance.

Is CIPLA a good stock for the long term?

StockLens rates CIPLA 5.1 out of 10 (Average) overall. Its long-term verdict is "Neutral (watchlist)": A mixed picture. Wait for better value or a clearer trend. Strengths: low debt, uptrend, high margins. Concerns: falling profits, weak ROE, cash burn.

Is CIPLA share overvalued?

CIPLA trades at a P/E of 38.7 against a Pharma & Healthcare median of 41.1, which StockLens rates as "In line with peers". Its price-to-book ratio is 3.17.

Is CIPLA good for short-term trading?

The trade bias for the next few weeks is "Long bias": Conditions favour buying dips over shorting. The price is 1.8% above its 200-day average and 14-day RSI is 54.

Which stocks are similar to CIPLA?

Similar Pharma & Healthcare stocks of comparable size include Dr. Reddy's Laboratories, Zydus Lifesciences, Aurobindo Pharma, Apollo Hospitals, Max Healthcare. You can compare up to 4 of them side by side on StockLens.

About Cipla Limited

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Stocks similar to CIPLA

Compare CIPLA with DRREDDY, ZYDUSLIFE, AUROPHARMA

Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.